Arbutus Biopharma Corp. (ABUS) is gearing up for a high-stakes year ahead on the legal front as it intensifies efforts to defend and enforce its proprietary lipid nanoparticle technology.
The lipid nanoparticle (LNP) technology, developed by Arbutus and Genevant Sciences Ltd., relies on microscopic particles built from four carefully selected types of fat-like molecules, called lipids, to shelter and protect mRNA molecules and help deliver them safely to target cells in the body, where they can enter the cells. Without this crucial delivery technology, mRNA would quickly degrade in the body and be ineffective.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.